Clinical Trials

Inclusion Criteria:

• Patients with a diagnosis of interstitial cystitis.
• One group of patients with interstitial cystitis who report a history or current use of pentosan polysulfate sodium.
• An age-matched control group of patients with interstitial cystitis who deny a history or current use of pentosan polysulfate sodium.

Exclusion Criteria:

• Patients without a diagnosis of interstitial cystitis.

Eligibility last updated 11/9/21. Questions regarding updates should be directed to the study team contact.

Residents of the 9-county area surrounding Rochester, MN with a diagnosis of interstitial cystitis identified via the Rochester Epidemiology Project (REP). All patients with a diagnosis of interstitial cystitis will be called via telephone to determine if they have ever taken or are currently taking PPS. Patients who have a history of PPS use or current PPS use will be recruited for a dilated funduscopic examination along with ultra-widefield fundus photography (Optos California icg, Dunfermline, Scotland, UK), ultra-widefield fundus autofluorescence (Optos California icg), spectral-domain macula optical coherence tomography (OCT) (Spectralis, Heidelberg Engineering), and near infrared reflectance (NIR) (Spectralis, Heidelberg Engineering) to screen for evidence of pentosan polysulfate maculopathy. Patients with a diagnosis of interstitial cystitis who denied a history of PPS use will also be recruited to an age-matched control cohort and undergo a dilated funduscopic examination along with ultra-widefield fundus autofluorescence, spectral-domain macula OCT, and NIR to screen for pattern dystrophy-like changes.